Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up Women only

Using antibiotics to prolong pregnancy after premature rupture of membranes

Official title: The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age

Run by Woman's · NCT04047849 · Data updated 2026-11-12

This study is testing if giving antibiotics to women with a premature rupture of membranes can help them keep their pregnancy going longer.

More Preterm Birth trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment34 (estimated)
SponsorWoman's
Academic / other
Drugs / interventionsimmunotherapy
Locations1 site (Baton Rouge, Louisiana)
StatusRecruiting
StartedAugust 28, 2019
Main results expectedJuly 1, 2021
Study endsJuly 1, 2021
Registry record updatedJanuary 11, 2021
Trial IDNCT04047849 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are pregnant women aged 18 or older, between 18 0/7 and 22 6/7 weeks of gestation, diagnosed with prelabor premature rupture of membranes without other complications.

Probably not a fit

Patients with fetal anomalies, diabetes, or other significant complications in their pregnancy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of outpatient oral antibiotics, specifically amoxicillin and azithromycin, in extending the duration of pregnancy after a premature rupture of membranes (PPROM) in women between 18 and 22 weeks of gestation. Participants diagnosed with PPROM will undergo a 24-hour monitoring period before being randomly assigned to either receive antibiotics or not. The primary outcome measured will be the number of days the pregnancy continues after the rupture. This study aims to provide insights into the management of PPROM and its implications for preterm birth.

Why it matters

Potential benefit: If successful, this approach could help prolong pregnancies in women experiencing PPROM, potentially improving outcomes for both mothers and infants.

How similar studies have gone: Other studies have explored the use of antibiotics in similar contexts, showing promising results, but this specific approach in previable PPROM is less commonly tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Singleton gestation
2. Gestational age of greater than 18 0/7 but less than or equal to 22 6/7
3. Diagnosis of prelabor premature rupture of membranes as determined by clinical examination noting either/or 1) visualization of amniotic fluid passing from the cervical canal and pooling in the vagina via sterile speculum examination, 2) a basic pH (i.e., positive nitrazine) test of vaginal fluid, 3) arborization (ferning) of dried vaginal fluid identified via microscopic examination, or 4) an amniotic fluid index (AFI) of less than 4cm
4. Greater than or equal to 18 years of age
5. Those with no known drug allergies or significant adverse reactions to azithromycin or amoxicillin
6. Afebrile at the time of presentation and throughout 24-hour observation period
7. Patient must be able to provide informed consent

Exclusion Criteria:

1. Fetal anomalies in current pregnancy
2. Diabetes mellitus, including both pre-gestational and gestational
3. Abnormal placentation
4. Poor dating with dating ultrasound performed later than or equal to 20 0/7 weeks
5. Current subchorionic hemorrhage or current vaginal bleeding on presentation
6. Hypertensive disease, including pre-gestational chronic hypertension, gestational hypertension and pre-eclampsia/eclampsia
7. History of amniocentesis during this pregnancy
8. History of cervical incompetence, history of cerclage in previous pregnancy or current cerclage in place
9. Current documented urinary tract infection or bacteriuria
10. Current documented genital tract infection (Chlamydia, gonorrhea, or trichomonas)
11. Immunocompromised (i.e., HIV positive, daily steroid use, or a history of autoimmune disease for which the patient is currently undergoing treatment with immunotherapy medication)

Where it's running

  • Woman's Hospital
    Baton Rouge, Louisiana, United States
    Recruiting

Study contacts

  • Principal investigator: Robert C Moore, MD — Woman's Hospital, Louisiana
  • Study coordinator: Felicia LeMoine, MD
  • Email: fvenab@lsuhsc.edu
  • Phone: 2252768164

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.